Integer (NYSE:ITGR – Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect Integer to post earnings of $1.68 per share and revenue of $466.4510 million for the quarter. Integer has set its FY 2025 guidance at 6.250-6.510 EPS.Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 23, 2025 at 9:00 AM ET.
Integer (NYSE:ITGR – Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.02). The firm had revenue of $476.00 million during the quarter, compared to the consensus estimate of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.30 earnings per share. On average, analysts expect Integer to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Integer Trading Down 0.2%
NYSE ITGR opened at $103.73 on Thursday. Integer has a 52 week low of $99.54 and a 52 week high of $146.36. The company has a 50 day moving average price of $104.99 and a 200 day moving average price of $113.32. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. The firm has a market cap of $3.63 billion, a PE ratio of 45.69, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97.
Institutional Investors Weigh In On Integer
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on ITGR shares. Wells Fargo & Company lowered their price objective on Integer from $152.00 to $132.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. Raymond James Financial lowered their price target on Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a report on Friday, July 25th. Wall Street Zen upgraded shares of Integer from a “hold” rating to a “buy” rating in a report on Saturday, August 30th. Truist Financial lowered their target price on shares of Integer from $137.00 to $121.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $137.29.
Get Our Latest Stock Report on ITGR
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Featured Stories
- Five stocks we like better than Integer
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Insider Trades May Not Tell You What You Think
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Where Do I Find 52-Week Highs and Lows?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.